| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| A H Stokes, D Y Lewis, L H Lash, W G Jerome, K W Grant, M Aschner, K E Vran. Dopamine toxicity in neuroblastoma cells: role of glutathione depletion by L-BSO and apoptosis. Brain research. vol 858. issue 1. 2000-04-25. PMID:10700589. |
dopamine (da), while an essential neurotransmitter, is also a known neurotoxin that potentially plays an etiologic role in several neurodegenerative diseases. |
2000-04-25 |
2023-08-12 |
Not clear |
| J O Rinn. Drug development for neurodegenerative diseases: role of PET. Annals of medicine. vol 31. issue 6. 2000-03-22. PMID:10680860. |
most current drugs for neurodegenerative diseases act through different neurotransmitter systems. |
2000-03-22 |
2023-08-12 |
human |
| J O Rinn. Drug development for neurodegenerative diseases: role of PET. Annals of medicine. vol 31. issue 6. 2000-03-22. PMID:10680860. |
positron emission tomography (pet) is a unique tool in the study of neurodegenerative diseases as it enables quantitative measurements of oxygen consumption, blood flow, energy metabolism and functioning of various neurotransmitter systems. |
2000-03-22 |
2023-08-12 |
human |
| F H Calderón, R von Bernhardi, G De Ferrari, S Luza, R Aldunate, N C Inestros. Toxic effects of acetylcholinesterase on neuronal and glial-like cells in vitro. Molecular psychiatry. vol 3. issue 3. 1998-10-08. PMID:9672900. |
acetylcholinesterase (ache), the enzyme involved in the hydrolysis of the neurotransmitter acetylcholine, has been implicated in non-cholinergic actions which may play a role in neurodegenerative diseases such as alzheimer's disease. |
1998-10-08 |
2023-08-12 |
Not clear |
| L J Fisher, H K Raymon, F H Gag. Cells engineered to produce acetylcholine: therapeutic potential for Alzheimer's disease. Annals of the New York Academy of Sciences. vol 695. 1993-12-10. PMID:8239296. |
an alternative strategy, that has been pursued in animal models of neurodegenerative disease, is to augment neurotransmitter function within the brain through tissue transplantation. |
1993-12-10 |
2023-08-12 |
rat |
| R H Edward. Neural degeneration and the transport of neurotransmitters. Annals of neurology. vol 34. issue 5. 1993-12-06. PMID:7902065. |
together with the identification of defects in glutamate transport from patients with amyotrophic lateral sclerosis, these observations suggest that neurotransmitter transport may have a major role in neurodegenerative disease. |
1993-12-06 |
2023-08-12 |
Not clear |
| P Bausero, M Schmitt, J L Toussaint, P Simoni, V Geoffroy, D Queuche, S Duclaud, J Kempf, C Quirin-Stricke. Identification and analysis of the human choline acetyltransferase gene promoter. Neuroreport. vol 4. issue 3. 1993-05-21. PMID:7682855. |
choline acetyltransferase (chat) is the key enzyme responsible for the synthesis of the neurotransmitter acetylcholine and is reduced in various central neurodegenerative diseases. |
1993-05-21 |
2023-08-12 |
human |
| B Meiste. [Transporters for neurotransmitters. A new gene family with characteristic features]. Lakartidningen. vol 90. issue 13. 1993-05-10. PMID:8096888. |
there is evidence suggesting neurotransmitter transporters to be involved in the pathophysiology of certain neurodegenerative diseases, and there are indications that drugs affecting transporter proteins may assume increasing clinical importance. |
1993-05-10 |
2023-08-12 |
Not clear |
| P Hartikainen, K J Reinikainen, H Soininen, J Sirviö, R Soikkeli, P J Riekkine. Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls. Journal of neural transmission. Parkinson's disease and dementia section. vol 4. issue 1. 1992-04-09. PMID:1347220. |
several neurotransmitter markers were investigated in the cerebrospinal fluid (csf) from patients with alzheimer's disease (ad) (n = 27), parkinson's disease (pd) (n = 35) and als (n = 26) and from control subjects (n = 34) to compare the possible alterations in the biochemical profiles of these different neurodegenerative diseases. |
1992-04-09 |
2023-08-11 |
human |
| T T Soncran. Age-associated functional impairments of specific neurotransmitter systems: detection by pharmacological brain metabolism studies and criteria for design of human investigations. International journal of clinical pharmacology research. vol 10. issue 1-2. 1990-09-24. PMID:1974889. |
specific criteria are proposed for pharmacological brain metabolism studies in man, using in vivo imaging, to identify functionally impaired neurotransmitter systems in aging and neurodegenerative diseases. |
1990-09-24 |
2023-08-11 |
human |
| J M Palacios, R Cortés, A Probs. Receptor plasticity in the human brain: some autoradiographic studies. Journal of receptor research. vol 7. issue 1-4. 1987-10-22. PMID:3040986. |
alterations of several neurotransmitter receptors in neurodegenerative diseases such as senile dementia and huntington's chorea, in lesions of specific brain pathways, like the visual pathway or after drug treatments, were examined. |
1987-10-22 |
2023-08-11 |
human |
| D M Gash, T J Collier, J R Slade. Neural transplantation: a review of recent developments and potential applications to the aged brain. Neurobiology of aging. vol 6. issue 2. 1985-09-11. PMID:3895013. |
in addition, the ability of grafted neurons to reinnervate damaged regions of the host brain and to ameliorate some neuroendocrine deficits, cognitive disorders and motoric dysfunctions in young adult rodents has suggested that transplantation therapy may be effective in treating human neurodegenerative diseases and neurotransmitter deficiencies related to aging. |
1985-09-11 |
2023-08-11 |
human |
| A C Foster, L P Miller, W H Oldendorf, R Schwarc. Studies on the disposition of quinolinic acid after intracerebral or systemic administration in the rat. Experimental neurology. vol 84. issue 2. 1984-06-07. PMID:6232146. |
the lack of an effective inactivation mechanism for extracellular quin in the brain negates quin's proposed role as a classical neurotransmitter substance, but may be of significance for the postulated effects of this compound in neurodegenerative diseases. |
1984-06-07 |
2023-08-12 |
human |